|
|
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Audrey Coilly
,
Claire Fougerou-Leurent
,
Victor De Ledinghen
,
Pauline Houssel-Debry
,
Christophe Duvoux
et al.
Journal articles
hal-01395132v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Achieving SVR Does Not Prevent From Fibrosis Progression In Patients With FCH: Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort
Mylene Sebagh
,
Claire Fougerou-Leurent
,
Georges-Philippe Pageaux
,
Vincent Leroy
,
Jerome Dumortier
et al.
Hepatology, 2017, 66, pp.872A-872A
Journal articles
hal-01684629v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Achieving SVR Does Not Prevent From Fibrosis Progession In Patients With FCH Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort
Mylene Sebagh
,
Claire Fougerou-Leurent
,
Georges-Philippe Pageaux
,
Vincent Leroy
,
Jerome Dumortier
et al.
Hepatology, 2017, 66, pp.872A-872A
Journal articles
hal-01769633v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation
Audrey Coilly
,
Mylene Sebagh
,
C. Fougerou-Leurent
,
Georges-Philippe Pageaux
,
Vincent Leroy
et al.
Journal articles
hal-03799246v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Hepatology, 2017, 63 (1 SUPP), pp.465A--465A
Journal articles
hal-01412958v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|